ConductScience.org, home

Paper35644166

Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials.

Danese S and 22 others. Lancet, 2022. Cited by 568 papers, by iCite.

Cite this record

ConductScience Library. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials. Papers, record 35644166. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/35644166

Download JSON
Disease
ulcerative colitis241 drugs
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials.
PubMed
Journal
Lancet
PubMed
Year
2022
PubMed
Publication types
Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial
PubMed
Citations, by iCite
568
iCite
Relative citation ratio, by iCite
51.9
iCite
Revised in PubMed
2022-11-04
PubMed

Authors23

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Danese SSilvio
2Vermeire SSéverine
3Zhou WWen
4Pangan ALAileen L
5Siffledeen JJesse
6Greenbloom SSusan
7Hébuterne XXavier
8D'Haens GGeert
9Nakase HHiroshi
10Panés JJulian
11Higgins PDRPeter D R
12Juillerat PPascal
13Lindsay JOJames O
14Loftus EV JrEdward V
15Sandborn WJWilliam J
16Reinisch WWalter
17Chen MHMin-Hu
18Sanchez Gonzalez YYuri
19Huang BBidan
20Xie WWangang

Source PubMed

See all 23 authorsDownload CSV of authors

Topics9

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Acne VulgarisMajor topic
Colitis, UlcerativeMajor topic
NasopharyngitisMajor topic
Creatine Kinase
Double-Blind Method
Heterocyclic Compounds, 3-Ring
Humans
Severity of Illness Index
Treatment Outcome

Source PubMed

Download CSV of topics

Trials4

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's recordSource
NCT02819635A Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis (UC)Derived from the trialYesClinicalTrials.gov
NCT03653026A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Ulcerative ColitisDerived from the trialYesClinicalTrials.gov
NCT06780683Efficacy and Safety of Upadacitinib in Inflammatory Bowel DiseaseResultsClinicalTrials.gov
NCT07442045Real-World Effectiveness and Safety of Upadacitinib Plus Vedolizumab vs Upadacitinib Monotherapy During Induction in Moderate-to-Severe Ulcerative ColitisBackgroundClinicalTrials.gov

Download CSV of trials

Comments and corrections4

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn PapersSource
Erratum in35988576Department of Error.https://conductscience.org/library/papers/35988576PubMed
Comment in35644164Upadacitinib for ulcerative colitis.https://conductscience.org/library/papers/35644164PubMed
Comment in35850194Upadacitinib: The New Jak Inhibitor in Town.https://conductscience.org/library/papers/35850194PubMed
Comment in36191310In active UC, upadacitinib induced and maintained remission.https://conductscience.org/library/papers/36191310PubMed

Download CSV of comments and corrections

Cited by368

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 568 citations.

PMIDTitleJournalYearIn PapersSource
42979323Real-world success of de-escalating upadacitinib induction dosing in ulcerative colitis is predicted by steroid-free clinical and biochemical remission, not induction duration.Crohns Colitis 3602026https://conductscience.org/library/papers/42979323PubMed
42976274Longitudinal timepoint assessment of patient-reported clinical disease activity in ulcerative colitis and Crohn's disease: suitability of a rapid Patient-Reported Outcome 2 (PRO-2) assessment.J Crohns Colitis2026https://conductscience.org/library/papers/42976274PubMed
42952524Benefit-risk profiling of advanced therapies in moderate-to-severe ulcerative colitis: a clustered network meta-analysis.Front Pharmacol2026https://conductscience.org/library/papers/42952524PubMed
42941186Inflammatory Bowel Disease: From Multifactorial and Metabolic Pathogenesis to Systemic Disease and Precision Medicine.Metabolites2026https://conductscience.org/library/papers/42941186PubMed
42928006[KASID Guidelines for the Medical Treatment of Ulcerative Colitis: 2026].Korean J Gastroenterol2026https://conductscience.org/library/papers/42928006PubMed
42923801Chinese expert consensus on the treatment of immune‑mediated inflammatory diseases with Janus kinase inhibitors.Rheumatol Immunol Res2026https://conductscience.org/library/papers/42923801PubMed
42918627Review: optimizing rescue therapy in acute severe ulcerative colitis using infliximab pharmacokinetics-a practical guide for clinicians.J Crohns Colitis2026https://conductscience.org/library/papers/42918627PubMed
42910148Paradoxical Massive Colonic Bleeding during Early Response to Upadacitinib in Acute Severe Ulcerative Colitis: A 3-Case Series.Inflamm Intest Dis2026https://conductscience.org/library/papers/42910148PubMed
42909122Biologic and small-molecule therapies for inflammatory bowel disease: mechanisms, comparative evidence and the emerging pipeline.Front Pharmacol2026https://conductscience.org/library/papers/42909122PubMed
42871137Stratified by baseline corticosteroid use: which advanced therapy works best for whom in ulcerative colitis?Front Med (Lausanne)2026https://conductscience.org/library/papers/42871137PubMed
42865982Acneiform eruption associated with Janus kinase inhibitors in pediatric inflammatory bowel disease: Case series and clinical management guidance.JPGN Rep2026https://conductscience.org/library/papers/42865982PubMed
42846532Integrative Transcriptomic and Genetic Analysis Prioritizes IRF1 as a Candidate Regulatory Gene Associated with Ulcerative Colitis.J Inflamm Res2026https://conductscience.org/library/papers/42846532PubMed
42813045From intestinal immune niches to systemic inflammation: programming cellular plasticity and immune redistribution across organs.Front Immunol2026https://conductscience.org/library/papers/42813045PubMed
42812453EPS deficiency aggravates intestinal mucosal inflammation and dysbiosis through disrupting macrophage polarization balance in ulcerative colitis.Front Immunol2026https://conductscience.org/library/papers/42812453PubMed
42812279Korean College of Rheumatology treatment recommendations for patients with axial spondyloarthritis: 2026 update.J Rheum Dis2026https://conductscience.org/library/papers/42812279PubMed
42798690Bridging the Treatment Access Gap: Janus Kinase Inhibitors as First-line Advanced Therapy for Inflammatory Bowel Disease in Resource-variable Settings.Euroasian J Hepatogastroenterol2026https://conductscience.org/library/papers/42798690PubMed
42781251Herpes zoster vaccination in inflammatory bowel disease: Evidence, guidelines, and reality.World J Virol2026https://conductscience.org/library/papers/42781251PubMed
42772941Optimising clinical trial design choices in inflammatory bowel disease.BMJ Open Gastroenterol2026https://conductscience.org/library/papers/42772941PubMed
42756780Dose-Escalated Upadacitinib for Refractory Myositis in Anti-Jo-1-Positive Antisynthetase Syndrome: A Case Report.Case Rep Rheumatol2026https://conductscience.org/library/papers/42756780PubMed
42739758Targeted Therapies in Inflammatory Bowel Disease: Mechanisms, Comparative Evidence, and Clinical Translation.J Clin Med2026https://conductscience.org/library/papers/42739758PubMed

See all 368 cited byDownload CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
JAK13716PubTator's text mininghttps://conductscience.org/library/genes/3716

Source NCBI Gene

Download CSV of genes

Drugs1

The drugs whose trials, in the Pipelines release, list the paper.

DrugChEMBL IDThe trials list it asTrialsIn Drugs and targets
UPADACITINIBCHEMBL3622821Results3https://conductscience.org/library/drugs/CHEMBL3622821

Source ChEMBL

Download CSV of drugs

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • References
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/35644166

GET https://conductscience.org/api/papers/v1/35644166/authors?page=2